Delivering excellence, innovation, and efficiency

X-Chem delivers excellence, innovation and efficiency at each stage of drug discovery. Since 2012, our medicinal chemists have been named as co-inventors on 24 projects, have filed over 100 patents and published more than 65 scientific papers. Our impressive track record includes 17 compounds reaching IND-enabling toxicology studies and seven compounds progressing to Phase I clinical trials or beyond.

Hit → Lead → Candidate: Click through our proven track record of reliability, efficiency and success.

ION CHANNELS

TARGET:
Sodium Channel Modulator

THERAPY AREA:
Epilepsy

GPCRS

TARGET:
H4 Antagonist

THERAPY AREA:
Inflammation

TRANSCRIPTION FACTORS

TARGET:
FOXO1 Inhibitor

THERAPY AREA:
Diabetes

KINASES

TARGET:
PINK1 Activator

THERAPY AREA:
Neurodegeneration

PROTEIN PROTEIN INTERACTIONS

TARGET:
NLRP3 Inhibitor

THERAPY AREA:
Inflammation

GPCRS

TARGET:
CXCR7 Modulator

THERAPY AREA:
Heart Failure

PROTEIN PROTEIN INTERACTIONS

TARGET:
KEAP1 Inhibitor

THERAPY AREA:
Neurodegeneration

GTPASES

TARGET:
Rac Inhibitor

THERAPY AREA:
Cancer

EPIGENETIC Regulators

TARGET:
Bromodomain Inhibitor

THERAPY AREA:
Inflammation and Cancer

EPIGENETIC Regulators

TARGET:
Bromodomain Inhibitor

THERAPY AREA:
Inflammation and Cancer

EPIGENETIC Regulators

TARGET:
Bromodomain Inhibitor

THERAPY AREA:
Inflammation and Cancer

EPIGENETIC Regulators

TARGET:
Bromodomain Inhibitor

THERAPY AREA:
Inflammation and Cancer

EPIGENETIC Regulators

TARGET:
EED (PRC2) Modulator

THERAPY AREA:
Blood Disorder

GPCRS

TARGET:
PAR2 Modulator

THERAPY AREA:
Inflammation

ION CHANNELS

TARGET:
Sodium Channel Modulator

THERAPY AREA:
Epilepsy

LIPIDS

TARGET:
Ferroptosis Inhibitor

THERAPY AREA:
Neurodegeneration